Urine Metabolic Profiling for Rapid Lung Cancer Screening: A Strategy Combining Rh-Doped SrTiO 3 -Assisted Laser Desorption/Ionization Mass Spectrometry and Machine Learning

• Published in: ACS applied materials & interfaces Vol. 16; no. 10; pp. 12302 - 12309
• Main Authors: Jia, Ke, Wang, Yawei, Jiang, Lixia, Lai, Mi, Liu, Wenlan, Wang, Liping, Liu, Huihui, Cao, Xiaohua, Li, Yuze, Nie, Zongxiu
• Format: Journal Article
• Language: English
• Published: United States 13.03.2024
• Subjects: lung cancer; urine metabolites; perovskite materials; laser desorption/ionization mass spectrometry; machine learning
• ISSN: 1944-8244; 1944-8252
• DOI: 10.1021/acsami.3c19007

Lung cancer ranks among the cancers with the highest global incidence rates and mortality. Swift and extensive screening is crucial for the early-stage diagnosis of lung cancer. Laser desorption/ionization mass spectrometry (LDI-MS) possesses clear advantages over traditional analytical methods for large-scale analysis due to its unique features, such as simple sample processing, rapid speed, and high-throughput performance. As n-type semiconductors, titanate-based perovskite materials can generate charge carriers under ultraviolet light irradiation, providing the capability for use as an LDI-MS substrate. In this study, we employ Rh-doped SrTiO (STO/Rh)-assisted LDI-MS combined with machine learning to establish a method for urine-based lung cancer screening. We directly analyzed urine metabolites from lung cancer patients (LCs), pneumonia patients (PNs), and healthy controls (HCs) without employing any pretreatment. Through the integration of machine learning, LCs are successfully distinguished from HCs and PNs, achieving impressive area under the curve (AUC) values of 0.940 for LCs vs HCs and 0.864 for LCs vs PNs. Furthermore, we identified 10 metabolites with significantly altered levels in LCs, leading to the discovery of related pathways through metabolic enrichment analysis. These results suggest the potential of this method for rapidly distinguishing LCs in clinical applications and promoting precision medicine.